Morgan Stanley cuts Pientzehuang's earnings forecasts and target price, maintains Underweight stance

Overview

This report is Morgan Stanley's Risk Reward Update on Zhangzhou Pientzehuang Pharmaceutical (600436.SS). The report cut 2025-30 earnings forecasts by 8-12%, mainly reflecting gross margin pressure from recent increases in natural musk and bezoar costs, and lowered the target price by 6% to Rmb165.00.

Core views

The core view is that the company benefits from a scarce TCM brand, an exclusive formula, and protected natural musk supply, and holds a leading position in patent medicines for liver disease; however, the current valuation has already priced in a great deal of optimism, with roughly 33x 2026e P/E not matching future growth. The report expects that continued increases in input costs will constrain end-market supply, slow liver-disease lozenge growth to single digits or lower, and put downward pressure on the valuation multiple.

Analysis framework

The report uses a risk-reward framework, assessing the target-price range across bull, base, and bear cases, and combines changes in earnings forecasts, raw-material cost trends, channel growth, pricing power, and valuation multiple shifts to judge the stock's risk-reward profile.

Methodology notes

• Valuation methodsDCF

  Discounted cash flow valuation

  The report uses a DCF approach, assuming an 8.0% cost of equity, a 4% terminal growth rate, a long-term ROE of 13.0%, and steady-state growth reached in 20 years.

• scenario_analysisRisk Reward

  Risk-reward scenario analysis

  The report sets bull, base, and bear cases to gauge potential upside and downside under different assumptions for revenue growth, earnings growth, raw-material supply, and valuation multiples.

• research_estimateMorgan Stanley ModelWare

  Morgan Stanley internal forecasting framework

  Unless otherwise noted, the report's metrics are based on Morgan Stanley's ModelWare framework; e denotes Morgan Stanley Research estimates.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• 600436.SS

  Research target

  Strengths

  Leading market share in the TCM liver-disease category, exclusive formula, protected natural musk supply, strong brand scarcity, and defensive growth in consumer channels.

  Weaknesses

  Rising raw-material costs compress gross margin, musk supply may limit output and sales, and the current valuation multiple is high.

  Comparison

  The report believes the current valuation of around 33x 2026e P/E is rich relative to the company's growth outlook; if the bull case plays out, valuation could return to above 40x, while the bear case would see clear multiple compression.

  Risks

  Further price increases could face consumer pushback, online platform sales could disappoint, raw-material supply could tighten, and manufacturing costs could rise.

Key data

• Target priceRmb165.00Target price cut by 6%.
• Earnings forecast revision2025-30 down 8-12%Mainly due to gross margin pressure from rising natural musk and bezoar costs.
• Bull caseRmb260.00Assumes consumers stock up in anticipation of price increases, quarterly revenue growth could reach 20%, and the valuation could recover to more than 40x, its historical high.
• Bear caseRmb90.00Assumes price increases hit a ceiling, musk supply becomes more constrained, and revenue and profit growth slow to single digits.
• Base case growth2024-27e revenue CAGR of about 5%, earnings CAGR of about 11%Driven by category growth, market share gains, and an improved business mix.
• Valuation multipleAbout 33x 2026e EPSThe report believes this is rich relative to the growth outlook.
• DCF assumptions8.0% cost of equity, 4% terminal growth rate, 13.0% long-term ROEAssumes steady-state growth is reached in 20 years.

Impact & implications

The report is cautious on 600436.SS: brand scarcity and defensive pricing power still provide support, but raw-material costs and supply constraints are eroding gross margin and growth visibility. Against an already elevated valuation, if sales growth fails to materially surprise on the upside or further price increases meet resistance, the stock is more likely to face valuation compression.

Risks

• Supply constraints and higher manufacturing costs for inputs such as natural musk and bezoar.
• Consumer pushback against further price increases, which could weigh on sales.
• Online platform sales may fall short of expectations.
• Liver-disease lozenge growth could slow to single digits or lower.
• The high valuation could face compression after the earnings forecast cuts.

What to watch

• Cost trends for natural musk and bezoar.
• Whether the PZH lozenge continues to see price increases and how well the market accepts them.
• Whether sales growth in the TCM hepatitis category exceeds 25%.
• Whether online channel contribution improves materially.
• Whether 2024-27e revenue and earnings CAGR can stay at base-case levels.